Table 4 PDXs as “Avatars” (DFS > TRG) in relation to patients follow-up.
From: Establishment of patient derived xenografts as functional testing of lung cancer aggressiveness
Stage | PD/D | DFS > TRG | NED | DFS > TRG | Total | DFS > TRG |
---|---|---|---|---|---|---|
Overall | ||||||
I | 6 | 1 (16,7) | 30 | 8 (26,7) | 36 | 9 (25) |
II | 12 | 4 (33,3) | 9 | 2 (22,2) | 21 | 6 (28,5) |
III | 33 | 8 (24.2) | 7 | 1 (14,3) | 40 | 9 (22,5) |
Grafted PDXs | ||||||
I | 1 | 1 (100) | 8 | 8 (100) | 9 | 9 (100) |
II | 6 | 4 (66.7) | 2 | 2 (100) | 8 | 6 (75) |
III | 19 | 8 (42.1) | 1 | 1 (100) | 20 | 9 (45) |